IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
AARON HOUSEMAN and NANCY ) HOUSEMAN, individually and on behalf ) of all others similarly situated, ) ) Plaintiffs, ) ) v. ) C.A. No. 8897-VCG ) ERIC S. SAGERMAN, THOMAS D. ) WHITTINGTON, CLINTON S. LAIRD, ) BROCK J. VINTON, RAYMOND ) IBARGUEN, GEORGE D. SERGIO and ) HEALTHPORT TECHNOLOGIES, ) LLC, ) Defendants. )
MEMORANDUM OPINION
Date Submitted: March 4, 2021 Date Decided: July 20, 2021
Eric M. Andersen, of ANDERSEN SLEATER SIANNI LLC, Wilmington, Delaware, Attorneys for Plaintiffs.
Stephen L. Caponi and Matthew B. Goeller, of K&L GATES LLP, Wilmington, Delaware, Attorneys for Defendant Thomas D. Whittington.
GLASSCOCK, Vice Chancellor This is the latest (alas, not the last) round of this multi-faceted and
testudinally-paced litigation over the acquisition of equity by the Plaintiffs, Aaron
and Nancy Houseman, in Universata, Inc. (“Universata”), and the distribution of the
proceeds of a cash-out merger of that entity. The current dispute involves alleged
wrongdoing of a stockholders’ representative in administration of the proceeds of
the merger. That matter, which involved many specific challenged decisions of the
stockholders’ representative, was assigned to a Special Master. The Special Master
issued a final report largely, but not entirely, supporting the decisions of the
stockholders’ representative. The Plaintiffs took exception to the report. They make
two general exceptions: that the report erroneously (1) supported the creation of an
escrow from merger proceeds to indemnify the purchaser, rather than requiring a
group of large stockholders (referred to in the merger agreement as the “Owners”)
to indemnify the purchaser out-of-pocket; and (2) applied an abuse of discretion
standard of review to the actions of the stockholders’ representative. The Plaintiffs
also make numerous objections to the specific findings of the Special Master’s final
report, some dependent on the success of the two general objections.
As required by our law, I have reviewed the thoughtful and thorough Special
Master’s final report de novo. 1 I find that the escrow fund was properly created from
sale proceeds, as called for in the merger agreement, and that the appropriate
1 See generally DiGiacobbe v. Sestak, 743 A.2d 180 (Del. 1999). 1 standard of review for actions of the stockholders’ representative is subjective good
faith. Unfortunately, ultimate resolution of the exceptions will require the parties to
inform me as to what effects these general rulings have on the specific exceptions.
An adumbration of the facts, and my reasoning, is below.
I. BACKGROUND
The Plaintiffs initiated this action in 2013, challenging the merger between
Universata and a wholly-owned subsidiary of HealthPort Technologies, LLC
(“HealthPort”).2 My Order of February 2, 2015 appointed Mr. James P. Dalle Pazze
(the “Special Master”) to review and make findings as to the administration of a
certain portion of the proceeds paid in connection with that merger; and to report
such findings to the Court in light of the allegations raised in paragraphs 50–62 of
the Plaintiffs’ Second Amended Complaint.3 In his Final Report, the Special Master
summarized both the stipulated facts and those facts found after trial. 4 I provide an
abridged version of the facts here as background for my analysis of the general
exceptions.5 I direct interested readers to Houseman v. Sagerman, 2015 WL
7307323 (Del. Ch. Nov. 19, 2015) for a more robust recitation.
2 See generally, e.g., Compl., Dkt. No. 1. 3 Order Appointing Special Master 1, Dkt. No. 129; see also Amended Verified Compl. ¶¶ 50–62, Dkt. No. 106. 4 Final Report by Special Master James P. Dalle Pazze 3–30, Dkt. No. 204 [hereinafter “FR”]. 5 Unless otherwise noted, the facts in this Memorandum Opinion were stipulated by the parties or proven by a preponderance of the evidence. To the extent there was conflicting evidence, I have weighed the evidence and made findings de novo based on the preponderance of the evidence. 2 A. The Parties
The Plaintiffs are former stockholders of Universata.6 Plaintiff Aaron
Houseman (“Houseman”) is also a former director of Universata. 7
Defendant Thomas D. Whittington (“Whittington”) was a director and
shareholder of Universata from February 2007 until June 1, 2011.8 Whittington also
served as the stockholders’ representative in connection with the merger, as
discussed further below.
The Plaintiffs became stockholders of Universata in 2009, when they
exchanged a portion of the debt Universata owed to them for Universata common
stock. 9 In connection with that transaction, the Plaintiffs entered into an agreement
with Whittington—then Universata’s Chairman—whereby, subject to certain
conditions, Whittington would personally purchase their 525,000 shares for $2.10
per share (the “Put Contract”).10 Houseman also became a director of Universata at
this time. 11
6 Pre-Trial Stip. and Order ¶ 1, Dkt. No. 178 [hereinafter “Stip.”]. 7 Id. ¶ 7. 8 Id. ¶ 2. 9 Id. ¶ 5. 10 Houseman v. Sagerman, 2015 WL 7307323, at *1 (Del. Ch. Nov. 19, 2015). 11 Stip. ¶ 7. 3 B. Factual Background
1. The Merger Agreement
In late 2010, HealthPort approached Universata about a potential
acquisition.12 On May 31, 2011, Universata and HealthPort executed a merger
agreement (the “Merger Agreement”) whereby Universata would merge into
HealthPort Acquisition Subsidiary, Inc., a wholly-owned subsidiary of HealthPort
(the “Merger”). 13
Pursuant to the Merger Agreement, HealthPort agreed to acquire Universata
for $17.5 million (the “Purchase Price”).14 Of the Purchase Price, $2.5 million was
held in escrow (the “Escrow Amount”). 15 In exchange, the stockholders of
Universata (the “Shareholders”) were to receive three forms of consideration: (1)
$1.02 per share in cash on June 1, 2011; (2) a right to receive up to $.27 per share in
cash to be distributed by July 1, 2012 from the Escrow Amount; and (3) shares in a
new company formed by Universata (Database Logic, Inc.) to hold a patent owned
by Universata that was not part of the Merger. 16
A subset of the Shareholders collectively owning over 72% of Universata’s
shares (the “Owners”) were parties to and signed the Merger Agreement—
12 Id. ¶ 8. 13 Id. ¶ 9. 14 JX 93, SMP-3052 (Merger Agreement § 1.3). 15 Id.; see also Stip. ¶ 11. 16 Stip. ¶ 11. The group defined as the Shareholders included holders of in-the-money options and warrants. JX 93, SMP-3050 (Merger Agreement § 3). 4 Commonwealth Ventures, Inc, Thomas D. Whittington, Brock J. Vinton, Richard F.
Whittington, and Clinton S. Laird.17 Houseman did not sign the Merger
Agreement. 18
2. The Shareholders’ Representative
Whittington was designated in the Merger Agreement to act as Universata’s
stockholders’ representative in connection with the Merger. 19 The Merger
Agreement provided that “[t]he Owners hereby appoint Thomas D. Whittington (the
“Shareholders’ Representative”) as their attorney-in-fact with full power . . . to
perform any and all acts necessary or appropriate in connection with the
Agreement.” 20
Among other responsibilities, the Shareholders’ Representative was charged
with “disbursing among the Shareholders the cash portion of the Purchase Price and
any other payments paid to Shareholders under this Agreement.” 21 It is undisputed
that the Shareholders’ Representative was responsible for distributing the Escrow
Amount. 22 Additionally, the Shareholders’ Representative was empowered to “do[]
17 See JX-93, SMP-3116–SMP-3120. 18 See Stip. ¶ 10. 19 See id. ¶ 12; JX 93, SMP-3111 (Merger Agreement § 12.16). 20 JX 93 SMP-3111 (Merger Agreement § 12.16(a)). I follow the Final Report in using the term “Shareholders’ Representative” when referring to Whittington in his capacity as such, and the term “Whittington” when referring to Whittington as an individual not acting in his capacity as Shareholders’ Representative. See FR 4 n.1. 21 Id. (Merger Agreement § 12.16(a)(ii)). 22 Stip. ¶ 11. 5 any and all things and tak[e] any and all action that the Shareholders’ Representative,
in such Person’s sole and absolute discretion, may consider necessary, proper or
convenient in connection with or to carry out the activities described in this Section
12.16 and the transactions contemplated by this Agreement.”23 The Merger
Agreement further provided that the actions of the Shareholders’ Representative
“shall be binding upon all of the Owners and Shareholders.” 24 The Shareholders’
Representative did not have “any duties or responsibilities except those expressly set
forth in [the Merger Agreement].”25
In carrying out his responsibilities, the Shareholders’ Representative was
entitled to rely upon “any statements furnished to it by any Owner, Shareholder or
the Purchaser, or any other evidence deemed by the Shareholders’ Representative to
be reliable and . . . shall be entitled to act on the advice of counsel selected by it.”26
3. Indemnification Obligations
The terms of the Merger required “no hair on the deal,” meaning that
Universata had to be essentially debt-free. 27 The Merger Agreement directs that the
Escrow Amount may be used to satisfy certain of Universata’s post-closing
obligations.28 For some, but not all, indemnification claims “the maximum amount
23 JX 93 SMP-3111 (Merger Agreement § 12.16(a)(iv)). 24 Id. SMP-3112 (Merger Agreement § 12.16(d)). 25 Id. SMP-3111 (Merger Agreement § 12.16(c)). 26 Id. 27 See Trial Tr. 378:1–378:19. 28 Stip. ¶ 11. 6 of Losses that [HealthPort was] entitled to recover” was limited to the Escrow
Amount. 29
The Merger Agreement addressed the possibility of Universata having either
liabilities or assets in excess of what the parties originally contemplated. The Merger
Agreement provided for a Purchase Price Adjustment, upward or downward, as
appropriate. This adjustment amount was to be paid out of the Escrow Amount, e.g.,
if the Adjusted Purchase Price was lower than the Purchase Price, HealthPort was
entitled to recover from the Escrow Amount. 30
The Merger Agreement also addressed the risk that Universata’s post-closing
revenues could be lower than originally contemplated. The Purchase Price was
subject to a downward adjustment if Universata’s revenues for the year following
the closing were less than $12 million—but not, I note, a reciprocal upward
adjustment if revenues were higher. 31 HealthPort was entitled to be paid from the
Escrow Amount in the event of such a revenue shortfall. 32
For certain claims, the Merger Agreement further provided that HealthPort
could recover up to an additional $3.68 million for a total Indemnity Cap (including
29 JX-93, SMP-3083 (Merger Agreement § 8.4(b)). 30 Id. SMP-3054–SMP-3056 (Merger Agreement § 1.6). If the Adjusted Purchase Price was higher than the Purchase Price, that amount was paid to the Shareholders’ Representative out of the Escrow Amount. See id. SMP-3055–SMP 3056 (Merger Agreement §§ 1.6(e)–(f)). 31 Id. SMP-3056 (Merger Agreement § 1.7). 32 Id. 7 the Escrow Amount) of $6.18 million.33 The Owners (and not the stockholders
generally) were jointly responsible for claims “in excess of or after depletion of the
Escrow Amount.” 34
I note that it is the role of the Shareholders’ Representative that is at issue
here. The fairness of the Merger itself to the stockholders of Universata is not at
issue.
C. Procedural History
The Special Master held a hearing in the form of a trial on October 24, 25, and
26, 2017. 35 He issued evidentiary rulings on October 30, 2018, which I affirmed in
part and overruled in part on May 2, 2019. 36 The Special Master issued his Draft
Report on March 2, 2020. 37 The Plaintiffs briefed exceptions to the Draft Report
from April until June 2020 38 and the Special Master issued his Final Report on
October 19, 2020. 39
33 Id. SMP-3082–SMP-3083 (Merger Agreement § 8.4). 34 Id. SMP-3082 (Merger Agreement § 8.2(c)). 35 Letter Ruling on Pls.’ Evidentiary Objections 1, Dkt. No. 185. 36 See generally id.; Tr. of Oral Arg. on Requests for Court Review of Evidentiary Rulings by the Special Master and Rulings of the Court, Dkt. No. 195. 37 Draft Report, Dkt. No. 196. 38 Pls.’ Br. in Supp. of Exceptions to the Special Master’s Draft Report, Dkt. No. 201; Def.’s Br. in Opp’n to Pls.’ Exceptions to the Special Master’s Draft Report, Dkt. No. 202; Pls.’ Reply Br. in Supp. of Exceptions to the Special Master’s Draft Report, Dkt. No. 203. 39 See generally FR. 8 The Plaintiffs took exceptions to the Final Report pursuant to Court of
Chancery Rule 144 (the “Plaintiffs’ Exceptions”).40 The parties fully briefed the
Plaintiffs’ Exceptions from November 2020 to January 2021. 41 I heard oral
argument on the exceptions on March 3, 2021 and consider the matter submitted for
my consideration as of that date.
II. LEGAL STANDARDS
When exceptions are taken to a Master’s final report, the Court of Chancery
applies a de novo standard of review with respect to issues of both law and fact.42
Typically, this court reviews exceptions “on the record before the Master, unless the
Court determines otherwise for good cause shown.” 43 A new hearing before the Vice
Chancellor is required only “where exceptions raise a bona fide issue as to
dispositive credibility determinations.”44 Otherwise, the Court may conduct its
review on the basis of the record without additional live testimony, as I have done
here.45
40 Exceptions to Special Master’s Final Report, Dkt. No. 205. 41 Pls.’ Br. in Supp. of Exceptions to the Special Master’s Final Report, Dkt. No. 206 [hereinafter “Pls.’ OB”]; Def.’s Br. in Opp’n to Pls.’ Exceptions, Dkt. No. 209 [hereinafter “Def.’s AB”]; Pls.’ Reply Br. in Supp. of Exceptions to the Special Master’s Final Report, Dkt. No. 210 [hereinafter “Pls.’ RB”]. 42 See Ct. Ch. R. 144(a); DiGiacobbe v. Sestak, 743 A.2d 180, 184 (Del. 1999). 43 Ct. Ch. R. 144(a). 44 DiGiacobbe v. Sestak, 743 A.2d at 184. 45 See id. 9 III. ANALYSIS
The Plaintiffs’ Exceptions consist of two parts.46 First, they identify two
general exceptions (the “General Exceptions”) challenging legal conclusions from
the Final Report: 47 (1) the Report found that the Escrow Amount was correctly
funded by all of Universata’s former shareholders from sale proceeds to pay post-
closing indemnification claims—instead, per the Plaintiffs, the Owners were solely
responsible for indemnifying HealthPort and should have funded the escrow
personally; and (2) the Special Master applied the wrong standard of review to
actions taken by the Shareholders’ Representative in connection with the Merger.48
The Plaintiffs also challenge the Final Report’s conclusions as to specific
distributions made by the Shareholders’ Representative out of the merger
consideration (the “Specific Exceptions”). I analyze the General Exceptions below.
A. How Should Indemnification Claims be Funded?
The Plaintiffs’ first General Exception contends that the Special Master
incorrectly interpreted the Merger Agreement to provide that certain of Universata’s
46 Whittington takes the position that the Plaintiffs’ General Exceptions have been waived. Def.’s AB 3, 6. For purposes of this Memorandum Opinion, I assume without deciding that no waiver has occurred. 47 The Plaintiffs describe their General Exceptions as “address[ing] two legal rulings from the Final Report: (a) former shareholders of an acquired Delaware corporation are on the hook to indemnify the first $2.5 million of obligations of the Delaware corporation; and (b) the shareholder representative has the ‘sole and absolute discretion’ to distribute the Merger Consideration however he sees fit.” Pls.’ OB 1. 48 At oral argument on the Plaintiffs’ Exceptions, the Plaintiffs clarified their position that the applicable standard is entire fairness. Tr. of March 4, 2021 Oral Arg. 10:10–11:6. 10 liabilities could paid from the Escrow Amount funded by Merger consideration.
This exception, I confess, is not entirely clear to me. The Plaintiffs do not appear to
dispute the express terms of the Merger Agreement providing that the Escrow
Amount may be used to satisfy certain pre- and post-closing obligations. Rather,
they seem to argue that the Escrow Amount should not have been established from
the total Purchase Price.
They note: “Section 8.2(a) of the Merger Agreement provides that the Owners
(a small subset of controlling shareholders that does not include the Plaintiffs) were
on the hook to cover the indemnification obligations owed to HealthPort—not all of
the shareholders.”49 They also point out that, while Section 1.3 of the Merger
Agreement “provides that a $2.5 million escrow would be set up, . . . it does not
provide [that the] escrow will be funded by all the shareholders for post-closing
obligations that were personally guaranteed by the Owners.” 50 Thus, their
exception, as I understand it, is that the Owners should have jointly deposited the
requisite $2.5 million into the Escrow account from their own funds.
Section 1.3 of the Merger Agreement provided that the Escrow Amount,
“shall be delivered in escrow to the Escrow Agent by the Purchaser to be disbursed
in accordance with that certain Escrow Agreement . . . and the remainder of the
49 Pls.’ OB 3 (emphasis in original). 50 Id. 5 (citing JX-93, SMP-3052). 11 Purchase Price will be paid to the Shareholders’ Representative, for itself and on
behalf of the Shareholders.”51 This provision makes clear that the Escrow Amount
was considered part of the $17.5 million Purchase Price. The Escrow Amount was
directly funded by the Purchaser, and no funding obligation was placed on the
Owners. Thus, any amounts permitted to be deducted from the Escrow Amount
would work a proportionate deduction on each Shareholders’ pro rata payout from
the Merger.
The wording of Section 8.2(a)—“each Owner agrees to” indemnify
HealthPort—does not change this analysis. Section 8.2 outlines the types of claims
the Owners are required to indemnify. As made clear in Section 8.2(c), HealthPort
“may seek recovery from such claims in excess of or after depletion of the Escrow
Amount directly from the Owners.” 52
Lastly, the Plaintiffs argue that, even if the Merger permitted HealthPort to be
indemnified from the Escrow Amount, that provision would be illegal and
unenforceable. They cite to Cigna Health & Life Insurance Company v. Audax
Health Solutions as support for the proposition that, as stockholders who did not
consent to the Merger, they cannot be bound by Universata’s indemnification
obligations.53 In Cigna, the Court concluded that the indemnification obligation
51 JX-93, SMP-3052 (emphasis added). 52 Id. SMP-3082 (emphasis added). 53 See Cigna Health & Life Ins. Co. v. Audax Health Sols., Inc., 107 A.3d 1082 (Del. Ch. 2014). 12 imposed by the merger agreement was void and unenforceable because it violated 8
Del. C. § 251. The post-closing adjustments permitted by the merger agreement as
indemnification were not limited in amount or in duration. Accordingly, the
stockholders would never have been able to know the exact value of the merger
consideration and the merger agreement failed to set forth “the cash, property, rights
or securities of any other corporation or entity which the holders of such shares are
to receive” as required by § 251(b)(5). Thus, Cigna did not reach the more general
question whether post-closing price adjustments can bind non-consenting
stockholders. Here, the Merger Agreement explicitly limits the Plaintiffs’
indemnification obligation to the Escrow Amount, and, with the exception of certain
fundamental representations and warranties guaranteed solely by the Owners, the
obligations do not survive indefinitely. The terms of the indemnification rights here
are both made explicit and limited in duration. Therefore, Cigna is inapplicable.
B. What Standard of Review Applies to the Actions of the Shareholders’ Representative?
Next, the Plaintiffs contend that the Special Master applied the wrong
standard of review to the actions of the Shareholders’ Representative. I understand
this exception to have two parts that are argued in the alternative. First, the Plaintiffs
reject the Special Master’s foundational assumption that the Shareholders’
Representative can act on their behalf at all. Per the Plaintiffs, because Section 12.16
states that only the Owners appoint the Shareholders’ Representative, that section 13 only applies to the Owners and not to them. Second, and assuming that the
Shareholders’ Representative is appointed on behalf of all Shareholders, the
Plaintiffs argue in briefing that the appropriate standard of review is that of “an
accounting.” At oral argument, they clarified that, by this, they mean entire fairness
review . 54 In other words, rather than the abuse of discretion standard applied by the
Special Master, the Shareholders’ Representative should bear the burden of
demonstrating that its expenditures were permissible and entirely fair to the
Shareholders.
1. The Shareholders’ Representative carries out the Merger Agreement on behalf of all Shareholders.
The fact that the Shareholders’ Representative was appointed by the Owners,
and not all Shareholders, does not limit his ability to act on behalf of the other
Shareholders. 55 The Merger Agreement provides that “[t]he Owners hereby appoint
Thomas D. Whittington (the “Shareholders’ Representative”) as their attorney-in-
fact with full power . . . to perform any and all acts necessary or appropriate in
connection with the Agreement.”56 The Merger Agreement further provides that the
actions of the Shareholders’ Representative “shall be binding upon all of the Owners
and Shareholders.”57 Generally, the actions of a stockholders’ representative are
54 Tr. of March 4, 2021 Oral Arg. 10:10–11:6. 55 See Aveta Inc. v. Cavallieri, 23 A.3d 157, 171, 178 (Del. Ch. 2010). 56 JX 93 SMP-3111 (Merger Agreement § 12.16(a)). 57 Id. SMP-3112 (Merger Agreement § 12.16(d)). 14 binding on all stockholders. 58 In Aveta Inc. v. Cavallieri, this Court addressed
whether non-signatories to a purchase agreement could be bound by the post-closing
actions of a shareholders’ representative. 59 The Court concluded that, because post-
closing adjustments are generally permissible as a matter of corporate law, the scope
of the contractual grant of authority to an agent to administer those adjustments is
irrelevant. Accordingly, “it does not matter whether . . . the Purchase Agreement
gave [the representative] authority to act on behalf of some, all, or none of [the]
stockholders. All that [Section 251] required was for [the representative] to be
designated as the individual who would follow the procedures and make or
participate in the determinations called for by the Purchase Agreement.”60 Here, as
in Aveta, the Merger Agreement designates the Shareholders’ Representative to
carry out the actions contemplated by that Agreement. Therefore, the Shareholders,
whether signatories or not, are bound by the actions and determinations of the
Shareholders’ Representative to the extent they are in accordance with the Merger
Agreement’s terms.
58 Cf. Cigna Health & Life Ins. Co. v. Audax Health Sols., Inc., 107 A.3d 1082, 1086 (Del. Ch. 2014) (noting that the stockholder representative’s actions are binding on the former stockholders); Aveta Inc. v. Cavallieri, 23 A.3d at 171, 178. 59 See generally Aveta Inc. v. Cavallieri, 23 A.3d 157. 60 Id. at 178. I note that the above holding was rendered as to Puerto Rico’s corollary to Section 251, but, in any event, it is persuasive authority. 15 2. The Shareholders’ Representative must act in subjective good faith.
The Special Master concluded that the appropriate standard of review of the
actions challenged in the Plaintiffs’ Specific Exceptions was whether the
Shareholders’ Representative had abused his discretion. The Plaintiffs argue that
Delaware law prohibits the contractual modification of a shareholders’
representative’s fiduciary duties and, therefore, that the Merger Agreement’s grant
of “sole and absolute discretion” is impermissible. In opposition to the Plaintiffs’
Exception, Whittington argues that the Shareholders’ Representative is not a
fiduciary, that he owes only contractual duties to the Shareholders, and that the
Merger Agreement grants him “sole and absolute discretion to take all necessary
steps to protect the Shareholders’ interests.”61 Neither, in my view, is entirely
correct.
Based on the language of the Merger Agreement, I conclude that the fiduciary
duties of the Shareholders’ Representative were intended to be limited to a duty of
subjective good faith. The Special Master’s Final Report correctly noted that a
shareholders’ representative, as attorney-in-fact for the selling shareholders,
generally assumes the obligations of a fiduciary.62 However, the duties of an
61 Def.’s OB 9. 62 FR 64; accord Winshall v. Viacom Int’l, Inc., 55 A.3d 629, 632 n.2 (Del. Ch. 2011) (noting that shareholders’ representative was attorney-in-fact for selling shareholders); Coleman v. Newborn, 948 A.2d 422, 429 (Del. Ch. 2007) (“An attorney-in-fact generally assumes the obligations of a fiduciary.”). 16 attorney-in-fact, like those of some other types of fiduciaries, may be modified by
contract.63 The Shareholders’ Representative is not, as the Plaintiffs seem to assume,
a corporate fiduciary.64 Rather, the Shareholders’ Representative is an agent of the
Shareholders whose powers and responsibilities are circumscribed by contract.65
The Merger Agreement explicitly rejected the Shareholders’ Representative’s
common law duties, by providing that “[t]he Shareholders’ Representative shall not
have any duties or responsibilities except those expressly set forth in this
Agreement.” 66 The Shareholders’ Representative’s duties are, broadly, “to perform
any and all acts necessary or appropriate in connection with this Agreement,”67
including “doing any and all things and taking any and all action that the
Shareholders’ Representative, in such Person’s sole and absolute discretion, may
consider necessary, proper or convenient in connection with or to carry out the
63 Nash v. Schock, 1997 WL 770706, at *3 (Del. Ch. Dec. 3, 1997) (“Because the fiduciary relationship between the principal and her attorney-in-fact is created and governed by contract, however, the principal may agree to waive or otherwise modify the implied fiduciary duty of loyalty and permit her attorney-in-fact to deal with the principal’s assets for the benefit of another or even for the benefit of the attorney-in-fact.”), aff’d and remanded, 732 A.2d 217 (Del. 1999); see also Gatz Properties, LLC v. Auriga Cap. Corp., 59 A.3d 1206, 1218 (Del. 2012) (noting that contractual provisions establishing a fiduciary standard in the limited liability company agreement may preclude the need for analysis of statutory standards). 64 See, e.g., Pls.’ OB 6. 65 See Fortis Advisors LLC v. Allergan W.C. Holding Inc., 2020 WL 2498068, at *2 (Del. Ch. May 14, 2020) (“Delaware law presumes parties are bound by the language of the agreement they negotiated.”). 66 See JX 93 SMP-3111 (Merger Agreement Section 12.16(c)) (“The Shareholders’ Representative shall not have any duties or responsibilities except those expressly set forth in this Agreement.”) 67 Id. (Merger Agreement Section 12.16(a)). 17 activities . . . contemplated by this Agreement.” 68 This standard, to my mind, is
equivalent to a duty of subjective good faith. The discretion of the Shareholder’s
Representative is cabined by his determination that a contemplated action is
“necessary, proper or convenient” in connection with carrying out the Merger
Agreement on behalf of the Shareholders. Should he act without such a
determination, he has breached a duty. The Merger Agreement authorizes him to
act on the Shareholders’ behalf. In that capacity, the Shareholders’ Representative
has an obligation to protect the Shareholders’ rights under the Merger Agreement.
The actions of the Shareholders’ Representative—including those challenged in the
Plaintiffs’ Exceptions—are appropriate, therefore, to the extent the Shareholders’
Representative subjectively determined those actions to be “necessary, proper or
convenient” to protect the Shareholders’ interests.69
IV. CONCLUSION
This concludes the first phase of my de novo review of the Final Report in
light of the Plaintiffs’ Exceptions. The parties should agree on a schedule to submit
brief memoranda on what exceptions remain pending following my decision here,
including whether any conclusions of the Special Master should be reconsidered
following my decision as to the standard of review applicable to actions of the
68 Id. (Merger Agreement Section 12.16(a)(iv)). 69 Conversely, the actions of the Shareholders’ Representative would not be appropriate if, for example, they were undertaken to protect his own interests or to benefit himself. 18 Shareholders’ Representative. Given the superannuated nature of this litigation, it
is my intention to address these issues without resubmission of any issues to the
Special Master, who is released from further service here. After I receive the parties’
supplemental memoranda, I will consider the Specific Exceptions submitted for
decision without need for further oral argument.